| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_feddba3d00c27f35e021fe5f4cb2dd5c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B25-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2020-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a66c5f1fe107299c344eb646f9b26cbd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89d94470eb633169561a8d226b74678a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eae8ea7cf303e4b8f4aab9bd439add7c |
| publicationDate |
2021-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021042204-A1 |
| titleOfInvention |
Biomarkers for cd47 blockade therapy |
| abstract |
Described herein are methods useful in treating a subject presenting with CD47+ cancer, by selecting for treatment with a CD47 blocking agent a subject having an altered level of expression of a marker gene selected from one, any two or all three of: reduced level of STAT2 expression; and elevated level of KIR inhibitor subgroup 1 expression; and elevated level of KIR inhibitor subgroup 2 expression. In addition to using single reference points, patients likely to receive a benefit from administration of a blocking agent include those who, before treatment, show a STAT2 level that is below baseline and either an elevated level of at least one of a KIR inhibitor subgroup 1 species or an elevated level of at least one of a KIR inhibitor subgroup 2 species. |
| priorityDate |
2019-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |